Active Surveillance for Prostate Cancer
Prostate CancerClosing the Cancer Gap

Active Surveillance for Prostate Cancer

Active Surveillance for Prostate Cancer
Thomas Barwick/Getty Images
By
Updated on October 9, 2025
by
Prostate cancer is the most common solid malignancy among men in the United States.

 According to the American Cancer Society, an estimated 313,780 men nationwide will be diagnosed with the disease in 2025.

 Prostate cancer comes in all kinds of varieties, from serious and life-threatening cases all the way to the more common, nonaggressive forms that are typically age related. The disease tends to occur in men as they age, so the presence of coexisting diseases can play a role in choosing treatment options.

What Is Active Surveillance?

After diagnosis, if eligible, you might consider an active surveillance approach instead of seeking treatment right away. What does this mean? You would basically meet regularly with your doctor and go through periodic testing to monitor your prostate and make sure there is no meaningful change in your cancer.

This would include a prostate-specific antigen (PSA) test about every six months and a digital rectal exam (DRE) at least once a year.

 Your doctor is also likely to obtain either an MRI of the prostate or a repeat biopsy of the prostate at no more often than yearly intervals.
If there are changes in your results, your doctor might recommend taking a different approach and discuss other treatment methods, including surgery and radiation.

When Might Active Surveillance Be the Best Option?

Active surveillance for prostate cancer is appropriate in patients with lower-risk prostate cancers that show no evidence of having spread outside the prostate.

 Patients with high-risk prostate cancers would not be eligible for this approach.
Observation of cancer as a concept seems confusing at first, but if you are diagnosed with low-risk cancer, based on findings from your biopsy, active surveillance avoids any side effects associated with cancer treatments like surgery or hormone therapy. Monitoring the cancer hasn’t been shown to result in an unacceptable likelihood of the disease progressing.

In people with other serious illnesses or of advanced age, active surveillance may help avoid difficult decisions relating to life expectancy.

 For example, an elderly gentleman with a lot of other conditions who is diagnosed with low-risk prostate cancer may not need to worry about treating it. It’s a tough conversation to have, but in these cases, other illnesses may be more severe and life-threatening, so treatment for that low-risk prostate cancer may not be needed.

Understandably, this is a difficult concept to accept. That being said, it’s important to have honest discussions with your family and your doctors about this treatment path.

co branded graphic for EH partnership with NY-Pres

Is Active Surveillance Safe?

Recent studies suggest we are correct to offer this approach to patients with low- or intermediate-risk prostate cancer. One study in JAMA Network Open speaks to the increasing acceptance of this treatment approach every year in the United States.

 Another study talks about safety with this approach in terms of cancer progression, which occurs only at extremely low rates.

Prostate Cancer Disparities

In the United States, prostate cancer disproportionally affects Black American men, who are both more likely to be diagnosed with prostate cancer and to die of the disease.

Why the cancer rate is so much higher among Black American men is complex and includes both social and environmental factors — but the reason could also partially be based on tumor biology. Active surveillance is an option for Black American patients, but their disease might be more aggressive; as a result, surgery or radiation might be discussed as an option sooner.

Many men are diagnosed with prostate cancer that can safely be watched, while many other men are diagnosed with aggressive prostate cancer that is dangerous to them. How do we navigate those two problems at the same time? It will take more study, research, and education of patients.

Learn more about active surveillance for prostate cancer from NewYork-Presbyterian Health Matters.

The Takeaway

  • Active surveillance is a viable option for men diagnosed with low-risk prostate cancer, enabling them to avoid the side effects of traditional treatments like surgery and hormone therapy.
  • Active surveillance involves regular monitoring through PSA tests and exams, and adjusting treatment if significant changes are found.
  • While studies suggest active surveillance is safe for many with low- to intermediate-risk prostate cancers, it is less appropriate for those with high-risk cancers due to the potential for rapid progression.
  • Disparities in prostate cancer outcomes, particularly among Black American men, highlight the importance of personalized care and the need for ongoing research and discussion about treatment options.
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Key Statistics for Prostate Cancer. American Cancer Society. May 30, 2025.
  2. Active Surveillance for Prostate Cancer. Mayo Clinic. November 15, 2023.
  3. Active Surveillance for Prostate Cancer. Johns Hopkins Medicine.
  4. Daskivich TJ et al. Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era. JAMA Internal Medicine. November 11, 2024.
  5. Ventimiglia E et al. Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden. JAMA Network Open. September 1, 2022.
  6. Bangma C et al. Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry. European Urology Oncology. April 2025.
  7. Why Black Men Should Consider Earlier Screening for Prostate Cancer. Memorial Sloan Kettering Cancer Center. January 17, 2025.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network

Daniel Landau, MD

Medical Reviewer

Daniel Landau, MD, is a distinguished board-certified hematologist-oncologist with a career that has spanned two eminent institutions: the Orlando Health Cancer Institute and the Medical University of South Carolina. With a specialized interest in genitourinary oncology and hematology, he has been at the forefront of managing both benign and malignant conditions.

Dr. Landau is a pioneering figure in integrating advanced technology into oncology, having served as a director of telemedicine services. Under his leadership, multiple innovative systems have been designed and piloted, all with a singular focus: enhancing the patient experience.

Beyond his clinical and technological endeavors, Landau is deeply committed to medical education. He has dedicated significant time and expertise to nurturing the skills of medical students, residents, and fellows, ensuring that the flame of knowledge and compassion burns bright in the next generation of oncologists.

See full bio
Joseph-Alukal-bio

Joseph Alukal, MD

Author
From NewYork-Presbyterian
Joseph Alukal, MD, is the director of men's health at NewYork-Presbyterian and Columbia University Irving Medical Center and fellowship director in andrology–male reproductive health. He maintains a busy clinical practice in men's health, male infertility, male sexual dysfunction, and general urology and has been named to Castle Connolly's Top Doctors New York Metro Area every year since 2016. Additionally, he maintains extensive clinical collaborative relationships with numerous IVF centers, primary care, and cardiology practices in and around the New York City area.

Dr. Alukal serves in a number of roles at a national and international level for professional specialty and subspecialty organizations, including the American Urological Association (AUA), the American Society for Reproductive Medicine (ASRM), and the Society for the Study of Male Reproduction (SSMR), of which he is a past-president and current board member. In his current role as a member of the AUA Ambassadors, he has lectured internationally to the Urologic Professional Societies of countries including India, Italy, and Bangladesh.

He has authored or been a co-author on more than 30 peer reviewed publications, and as well is the lead editor of the book Design and Implementation of the Modern Men's Health Center.

See full bio
See Our Editorial PolicyMeet Our Health Expert Network